Center for Scientific Review; Notice of Closed Meetings, 14894-14895 [2024-04253]
Download as PDF
<![CDATA[
14894
Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices
III. Petitions
Anyone with knowledge that any of
the dates as published are incorrect may
submit either electronic or written
comments and, under 21 CFR 60.24, ask
for a redetermination (see DATES).
Furthermore, as specified in § 60.30 (21
CFR 60.30), any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of
§ 60.30, including but not limited to:
must be timely (see DATES), must be
filed in accordance with § 10.20, must
contain sufficient facts to merit an FDA
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
Nos. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: February 23, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
16:39 Feb 28, 2024
Jkt 262001
Dated: February 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–04254 Filed 2–28–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
[FR Doc. 2024–04218 Filed 2–28–24; 8:45 am]
VerDate Sep<11>2014
Conferences and Scientific Meetings (Parent
R13 Clinical Trial Not Allowed).
Date: March 26–28, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G53,
Rockville, MD 20852 (Video Assisted
Meeting).
Contact Person: Caitlin A. Brennan, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G53, Rockville, MD
20852, (301) 761–7792, caitlin.brennan2@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Instrumentation, Environmental,
and Occupational Safety.
Date: March 20–21, 2024.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Hybrid Meeting).
Contact Person: Joonil Seog, SCD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–402–9791, joonil.seog@nih.gov.
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Health Services Research: Health Information
Technology to Improve Care Delivery.
Date: March 21–22, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mary Kate Baker, DRPH,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–5117, katie.baker2@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; NIH
Director’s New Innovator Award Program
(DP2).
Date: March 21–22, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Eugene Carstea, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4130,
MSC 7818, Bethesda, MD 20892, (301) 408–
9756, carsteae@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Disease Management, Risk
Prevention, and Health Behavior Change.
Date: March 21–22, 2024.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jennifer Di Noia, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000E,
Bethesda, MD 20892, (301) 594–0288,
dinoiaj2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Metabolism and
Reproductive Sciences.
Date: March 21, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Hui Chen, MD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 6164, Bethesda, MD 20892, 301–
435–1044, chenhui@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Research
Enhancement Awards: Molecular Genetics
and Genomics.
Date: March 21, 2024.
Time: 1:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\29FEN1.SGM
29FEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mollie Kim Manier, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–0510, mollie.manier@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–OD–
24–001: Study and Techniques on Intimate
Partner Violence in Different Populations.
Date: March 21, 2024.
Time: 12:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Helena Eryam Dagadu,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3137,
Bethesda, MD 20892, (301) 451–6273,
dagaduhe@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Communication, Motor Function,
and Human Development.
Date: March 22, 2024.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Louise Hargrave,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
Bethesda, MD 20892, (301) 443–7193,
hargravesl@mail.nih.gov.
Name of Committee: Infectious Diseases
and Immunology B Integrated Review Group;
HIV Comorbidities and Clinical Studies
Study Section.
Date: March 26–27, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin Georgetown, 2350 M
Street NW, Washington, DC 20037.
Contact Person: Shannon J. Sherman,
Ph.D., Scientific Review Officer, Center for
Scientific Review, The National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–594–0715, shannon.sherman@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: SBIR/STTR Commercialization
Readiness Pilot (CRP) Program.
Date: March 26–27, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marie-Jose Belanger, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm 6188, MSC
7804, Bethesda, MD 20892, 301–435–1267,
belangerm@csr.nih.gov.
VerDate Sep<11>2014
16:39 Feb 28, 2024
Jkt 262001
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Projects: Neuroscience and Genetics of Drug
Abuse.
Date: March 26, 2024.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jacek Topczewski, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002A1,
Bethesda, MD 20892, (301) 594–7574,
topczewskij2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 26, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–04253 Filed 2–28–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Winter 2024 CISA SBOM-a-Rama
Cybersecurity and
Infrastructure Security Agency (CISA),
Department of Homeland Security
(DHS).
ACTION: Announcement of meeting.
AGENCY:
CISA will facilitate a public
event to build on existing communityled work around Software Bill of
Materials (SBOM) on specific SBOM
topics. The goal of this meeting is to
help the broader software and security
community understand the current state
of SBOM and what efforts have been
made by different parts of the SBOM
community, including CISA-facilitated,
community-led work and other activity
from sectors and governments.
DATES: February 29, 2024, 12 p.m. to 4
p.m. EST.
ADDRESSES: The event will be virtual.
Connection and dial-in information for
this virtual event will be available one
week before this event at https://
www.cisa.gov/news-events/events/sbomrama-winter-2024.
FOR FURTHER INFORMATION CONTACT:
Allan Friedman, 202–961–4349, sbom@
cisa.dhs.gov.
SUPPLEMENTARY INFORMATION: An SBOM
has been identified by the cybersecurity
community as a key aspect of modern
cybersecurity, including software
security and supply chain security.
SUMMARY:
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
14895
Executive Order (E.O.) 14028 declares
that ‘‘the trust we place in our digital
infrastructure should be proportional to
how trustworthy and transparent that
infrastructure is, and to the
consequences we will incur if that trust
is misplaced.’’ 1 SBOMs play a key role
in providing this transparency.
E.O. 14028 defines SBOM as ‘‘a
formal record containing the details and
supply chain relationships of various
components used in building
software.’’ 2 The E.O. further notes that
‘‘software developers and vendors often
create products by assembling existing
open source and commercial software
components. The SBOM enumerates
these components in a product.’’ 3
Transparency from SBOMs aids
multiple parties across the software
lifecycle, including software developers,
purchasers, and operators.4 Recognizing
the importance of SBOMs in
transparency and security, and that
SBOM evolution and refinement is
likely to be most effective coming from
the community; CISA is facilitating a
public event which is intended to
advance the software and security
communities’ understanding of SBOM
creation, use, and implementation
across the broader technology
ecosystem.
I. SBOM Background
The idea of an SBOM is not novel.5
It has been discussed and explored in
the software industry for years, building
on industrial and supply chain
innovations.6 Academics identified the
potential value of a ‘‘software bill of
materials’’ as far back as 1995,7 and
tracking use of third-party code is a
longstanding software best practice.8
1 E.O. 14028, Improving the Nation’s
Cybersecurity, 1, 86 FR 26633 (May 17, 2021).
2 Id. at 10(j), 86 FR 26633 at 26646 (May 17,
2021).
3 Ibid.
4 Ibid.
5 A brief summary of the history of a software bill
of materials can be found in Carmody, S., Coravos,
A., Fahs, G. et al. Building resilient medical
technology supply chains with a software bill of
materials. npj Digit. Med. 4, 34 (2021). https://
doi.org/10.1038/s41746-021-00403-w.
6 See ‘‘Toyota Supply Chain Management: A
Strategic Approach to Toyota’s Renowned System’’
by Ananth V. Iyer, Sridhar Seshadri, and Roy
Vasher—a work about Edwards Deming’s Supply
Chain Management https://books.google.com/
books/about/Toyota_Supply_Chain_Management_
A_Strateg.html?id=JY5wqdelrg8C.
7 Leblang D.B., Levine P.H., Software
configuration management: Why is it needed and
what should it do? In: Estublier J. (eds) Software
Configuration Management Lecture Notes in
Computer Science, vol. 1005, Springer, Berlin,
Heidelberg (1995).
8 The Software Assurance Forum for Excellence
in Code (SAFECode), an industry consortium, has
released a report on third party components that
E:\FR\FM\29FEN1.SGM
Continued
29FEN1
]]>Agencies
[Federal Register Volume 89, Number 41 (Thursday, February 29, 2024)]
[Notices]
[Pages 14894-14895]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-04253]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Instrumentation, Environmental, and
Occupational Safety.
Date: March 20-21, 2024.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Hybrid Meeting).
Contact Person: Joonil Seog, SCD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, 301-402-9791,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics in Health Services Research: Health Information
Technology to Improve Care Delivery.
Date: March 21-22, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mary Kate Baker, DRPH, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-5117,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; NIH Director's New Innovator Award Program (DP2).
Date: March 21-22, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Eugene Carstea, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4130, MSC 7818, Bethesda, MD
20892, (301) 408-9756, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Disease Management, Risk Prevention, and
Health Behavior Change.
Date: March 21-22, 2024.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jennifer Di Noia, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000E, Bethesda, MD 20892, (301)
594-0288, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Topics in Metabolism and Reproductive
Sciences.
Date: March 21, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Hui Chen, MD, Scientific Review Officer, Center
for Scientific Review, National Institutes of Health, 6701 Rockledge
Drive, Room 6164, Bethesda, MD 20892, 301-435-1044,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Research Enhancement Awards: Molecular Genetics and Genomics.
Date: March 21, 2024.
Time: 1:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 14895]]
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mollie Kim Manier, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-0510,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; RFA-OD-24-001: Study and Techniques on Intimate Partner
Violence in Different Populations.
Date: March 21, 2024.
Time: 12:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Helena Eryam Dagadu, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3137, Bethesda, MD 20892, (301)
451-6273, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Communication, Motor Function, and Human
Development.
Date: March 22, 2024.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Louise Hargrave, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170, Bethesda, MD 20892, (301)
443-7193, [email protected].
Name of Committee: Infectious Diseases and Immunology B
Integrated Review Group; HIV Comorbidities and Clinical Studies
Study Section.
Date: March 26-27, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The Westin Georgetown, 2350 M Street NW, Washington, DC
20037.
Contact Person: Shannon J. Sherman, Ph.D., Scientific Review
Officer, Center for Scientific Review, The National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-594-0715,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: SBIR/STTR Commercialization Readiness Pilot
(CRP) Program.
Date: March 26-27, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm 6188, MSC 7804, Bethesda, MD 20892,
301-435-1267, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Program Projects: Neuroscience and Genetics of Drug Abuse.
Date: March 26, 2024.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jacek Topczewski, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002A1, Bethesda, MD 20892, (301)
594-7574, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: February 26, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-04253 Filed 2-28-24; 8:45 am]
BILLING CODE 4140-01-P
